Eye Drug Lucentis Recommended by UK’s NICE to Treat Wet AMD
Sunday, April 20, 2008
Novartis AG's Lucentis drug against wet age-related macular degeneration (AMD) received a recommendation from the UK's National Institute for Health and Clinical Excellence (NICE) for use on the National Health Service.
Lucentis should be used for about 20 pct of patients with AMD, a condition which causes sight loss and blindness, when both eyes are affected, NICE said in a statement last night.
NICE said it does not recommend the use of OSI Pharmaceuticals Inc (nasdaq: OSIP - news - people )'s rival eye treatment Macugen.
0 comments:
(Click on the image to view full size)
Post a Comment